Edgewise Therapeutics, Inc.EWTXNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +42.67% | +8.64% | +12.22% | +12.45% | +11.38% |
| Weighted Average Shares Diluted Growth | +42.67% | +8.64% | +12.22% | +12.45% | +11.38% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +43.17% | -17.95% | +15.36% | +14.12% | +13.51% |
| Book Value per Share Growth | +0.95% | -26.06% | +2.83% | +1.62% | +2.11% |
| Debt Growth | -12.50% | -13.16% | -12.32% | -5.83% | -15.77% |
| R&D Expense Growth | +31.38% | +32.73% | +9.38% | +16.32% | +19.86% |
| SG&A Expenses Growth | +48.43% | +30.36% | +21.88% | +14.23% | +35.06% |